<DOC>
	<DOCNO>NCT00006358</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Thalidomide may stop growth cancer stop blood flow tumor . PURPOSE : Phase II trial study effectiveness combine temozolomide thalidomide treat patient recurrent progressive brain tumor .</brief_summary>
	<brief_title>Temozolomide Plus Thalidomide Treating Patients With Recurrent Progressive Brain Tumor</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy temozolomide thalidomide patient recurrent progressive supratentorial glioblastoma multiforme gliosarcoma . II . Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients receive oral temozolomide daily day 1-5 oral thalidomide daily day 1-28 . Treatment repeat every 28 day maximum 24 course absence disease progression unacceptable toxicity . Patients follow 1 month survival . PROJECTED ACCRUAL : A total 40 patient accrue study within 4-5 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm supratentorial glioblastoma multiforme gliosarcoma Must evidence tumor recurrence progression MRI scan fail prior radiotherapy Bidimensionally measurable enhance residual disease MRI CT scan Prior recent resection recurrent progressive tumor allow following condition apply : Recovered surgery Residual evaluable disease present artifactual postsurgical enhancement Baseline MRI CT scan perform within 14 day prior study steroid dose stable least 57 day PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : At least 8 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : SGPT le 2 time normal Alkaline phosphatase less 2 time normal Bilirubin le 1.5 mg/dL Renal : BUN creatinine less 1.5 time normal Other : Not pregnant nursing Negative pregnancy test Fertile patient must use one highly effective method contraception , AND one additional effective method contraception least 4 week , , 8 week study No peripheral neuropathy great grade 1 No active infection No illness would obscure toxicity alter drug metabolism No concurrent serious medical illness No prior cancer within past 3 year except nonmelanoma skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No prior thalidomide No concurrent biologic therapy cancer Chemotherapy : No 1 prior chemotherapy regimen At least 3 week since prior chemotherapy ( 2 week vincristine 6 week nitrosoureas ) No concurrent chemotherapy cancer Endocrine therapy : See Disease Characteristics No concurrent endocrine therapy cancer Radiotherapy : See Disease Characteristics No concurrent radiotherapy cancer Surgery : See Disease Characteristics No concurrent surgery cancer Other : Recovered prior therapy No concurrent investigational drug cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>